Among GLP-1 receptor agonists, liraglutide is the only one shown to significantly lower the risk of dying from heart-related causes in people with type 2 diabetes and kidney disease, reducing that risk by about one-third compared to no treatment.
Claim Context
Liraglutide, a GLP-1 receptor agonist, reduces cardiovascular death by 31% compared to placebo in patients with type 2 diabetes and chronic kidney disease, with a risk ratio of 0.69 (95% CI: 0.52–0.90), and is the only GLP-1 RA in the analysis to show significant benefit for this outcome.
“liraglutide (RR [95% CI]; 0.69 [0.52–0.90]) was better than placebo... liraglutide was the only intervention to show efficacy in CVD compared with placebo.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review of head-to-head RCTs comparing liraglutide directly with other GLP-1 RAs would definitively establish whether its cardiovascular death benefit is unique among this drug class.
A systematic review and meta-analysis of all completed and ongoing head-to-head randomized controlled trials comparing liraglutide 1.8 mg/day directly with semaglutide 1 mg/week, dulaglutide 1.5 mg/week, or exenatide 2 mg/week in adults with type 2 diabetes and CKD (eGFR 25–60 mL/min/1.73m²), with cardiovascular death as primary endpoint, minimum follow-up of 3 years, and adjudicated outcomes by independent committee.
A direct head-to-head RCT would establish whether liraglutide causes a greater reduction in cardiovascular death than other GLP-1 RAs in the same population, eliminating indirect comparison bias.
A multicenter, double-blind, parallel-group RCT enrolling 1,800 adults with type 2 diabetes and CKD (eGFR 25–60 mL/min/1.73m², UACR ≥300 mg/g), randomized 1:1:1 to liraglutide 1.8 mg/day, semaglutide 1 mg/week, or exenatide 2 mg/week, with primary outcome being time to cardiovascular death over 3 years, powered at 90% to detect a 25% relative risk reduction.
A prospective cohort study would determine whether real-world use of liraglutide is associated with lower rates of cardiovascular death than other GLP-1 RAs in routine clinical practice.
A prospective cohort study following 15,000 adults with type 2 diabetes and CKD across multiple healthcare systems, matched by propensity score for age, eGFR, UACR, and comorbidities, comparing incident cardiovascular death over 5 years between those initiating liraglutide, semaglutide, or exenatide, with outcomes adjudicated by death certificates and hospital records.
A case-control study could assess whether prior use of liraglutide is less common among patients who died from cardiovascular causes compared to those treated with other GLP-1 RAs.
A nested case-control study within a large electronic health record database identifying 400 patients with type 2 diabetes who died from cardiovascular causes within 3 years and matching each to 4 controls who survived, comparing prior exposure to liraglutide, semaglutide, or exenatide, adjusting for baseline eGFR, UACR, HbA1c, and cardiovascular disease.
A cross-sectional study could describe the association between current medication use and prevalence of prior cardiovascular death at a single point in time.
A cross-sectional analysis of 7,000 adults with type 2 diabetes and CKD from primary care clinics, recording history of cardiovascular death and current use of liraglutide, semaglutide, or exenatide, adjusting for age, diabetes duration, and blood pressure.